Skip to main content
Terug
Watch Compare

ZyVersa Therapeutics, Inc.

Datakwaliteit: 83%
ZVSA
OTC Manufacturing Chemicals
€ 0,22
▲ € 0,03 (15,79%)
Marktkapitalisatie: 1,54 M
Prijs
€ 0,19
Marktkapitalisatie
1,54 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -5,11 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio0,08
Interest Coverage-49,67

Waardering

PE (TTM)
-0,06
Boven sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,1 -1,5
P/B — 1,6
ROE % — -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q32024 -€ 1,60 -€ 2,43 -51,9%
Q22024 -€ 3,75 -€ 3,31 +11,7%
Q12024 -€ 3,70 -€ 4,53 -22,4%
Q42023 -€ 21,40 -€ 1.041,80 -4768,2%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -24,95 M
ROE N/A ROA -241,30%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -5,11 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,08
Interest Coverage -49,67 Asset Turnover N/A
Working Capital -11,77 M Tangible Book Value -11,73 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,06 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -332,49%
Market Cap 1,54 M Enterprise Value 1,54 M
Per Share
EPS (Diluted TTM) -4,18 Revenue / Share N/A
FCF / Share -0,63 OCF / Share -0,63
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 20,50%
SBC-Adj. FCF -5,48 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2022 FY2023 FY2021
Revenue — — — — —
Net Income -24,95 M -9,41 M -75.018,0 -98,30 M -240.700,0
EPS (Diluted) -4,18 -8,48 — -108,97 —
Gross Profit — — — — —
Operating Income -25,49 M -9,14 M -820.068,0 -107,75 M -235.267,0
EBITDA — — — — —
R&D Expenses 1,11 M 1,78 M 399.894,0 3,21 M —
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense -513.209,0 -269.856,0 — 457,0 —
Income Tax -851.659,0 6.745,0 -745.050,0 -9,46 M —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2022 FY2023 FY2021
Total Assets 347.901,0 20,60 M 118,51 M 22,11 M 77,14 M
Total Liabilities 12,73 M 12,08 M 18,51 M 11,04 M 3,65 M
Shareholders' Equity -12,39 M 8,52 M 99,66 M 11,07 M -2,26 M
Total Debt — — — — —
Cash & Equivalents — — — — 928.389,0
Current Assets 347.901,0 1,72 M 6,36 M 3,35 M 1,18 M
Current Liabilities 12,73 M 11,23 M 8,19 M 10,19 M 276.835,0